Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Chief Commercial Officer | February 26, 2019 | February 28, 2019 |
| POLARITYTE, INC.PTE · Entity 117561 | Chf. Exec. Off. & Pres. | July 18, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date February 26, 2019 · Filed February 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 9,000 |
Reported balance
After 2019-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-26 · Grant · Acquired 9,000 · Balance 9,000 F1: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.47 · Expires 2028-01-24 | Direct | 3,777 |
Reported balance
After 2019-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-27 · Grant · Acquired 3,777 · Balance 3,777 F2: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020.
F2: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4.
F3: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4.
F4: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022.
POLARITYTE, INC.
Report date July 18, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,794 |
Reported balance
After 2022-07-18 transaction · row 1
1 source rowRow 1 · 2022-07-18 · Tax withholding · Disposed 474 · Balance 45,794 F1: The shares were withheld by the Issuer to cover withholding taxes resulting from vesting of restricted stock units that were previously reported on Table I. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to cover withholding taxes resulting from vesting of restricted stock units that were previously reported on Table I.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2017 Filed Dec 1, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 5,250 | $54.48 | $286,020.00 |
DisclosureSEC source: 0001171843-17-007396 · formfour.xml · nonDerivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,650 F1 · price: On November 30, 2017, Mr. Hague sold 5,250 shares in multiple trades ranging from $54.20 to $54.98. The price reported above reflects the weighted average sale price. Mr. Hague undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001207 · formfour.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000587 · formfour.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.